Technical Whitepaper | Upstream Antibody Qualification

Ultra-Sensitive Assay Development Starts Before Detection

Ultra-sensitive detection platforms can measure extremely low concentrations, but detection results alone do not provide the information needed to determine whether an antibody has suitable binding kinetics, cross-reacts with related targets, remains consistent across batches, or forms a compatible assay pair. FOPPR provides this upstream evidence through real-time binding analysis and sequential epitope binning of up to four antibodies on one sensor.

Once qualified, selected antibody pairs can be transferred to FONLISA, Simoa, or another compatible platform for downstream optimization and quantification.

Prepared by the Instant NanoBiosensors Technical Team

Ultra-sensitive detection and upstream antibody qualification solve different problems. FOPPR complements the downstream detection platform rather than competing with it.
Real-Time Binding Kinetics Multiple epitope binning Cross-Reactivity Assessment Batch Comparison Ultra-Sensitivity Downstream Platform Flexibility Decentralized Deployment

The Problem

Why Sensitivity Alone Is Not Enough

A low LoD has little value if the assay is measuring the wrong target.

Many clinically important biomarkers require femtomolar or attomolar detection. But detecting a small signal is only meaningful when it originates from the intended target. Greater sensitivity can reveal the correct biomarker, or magnify signals caused by background, cross-reactivity, and poor antibody-pair selection.

Failure mode 1The “Needle in a Haystack” Problem

The target is difficult to distinguish from background.

Low target abundance, nonspecific binding, blank variation, and matrix interference can obscure the true signal even when the instrument is highly sensitive.

Failure mode 2The “Lookalike” Problem

The assay must distinguish the intended molecular form.

Isoforms, fragments, unmodified proteins, and related post-translational modifications may produce misleading signals when antibody specificity is insufficient.

Failure mode 3The “Spatial” Problem

Strong antibodies do not always form a strong pair.

Antibodies may compete for overlapping regions, create steric interference, dissociate too quickly, or perform differently when their capture and detector roles are reversed.

Failure mode 4The “Reproducibility” Problem

Antibody performance can change across batches and conditions.

Binding behavior may vary with antibody batch, buffer composition, reagent formulation, storage, handling, and sample environment.

These are antibody-selection problems, not detection-limit problems. They should be addressed before the assay is transferred to an ultra-sensitive detection platform.

The Solution

From Selection to Detection

Make the antibody decisions before scaling sensitivity

FOPPR provides the binding, specificity, and compatibility evidence needed to select antibody candidates before transferring them to FONLISA, Simoa, or another compatible detection platform. Unsuitable candidates can be excluded earlier, reducing downstream optimization and development risk. After assay development, FOPPR can continue to support antibody batch-to-batch comparison and reagent-condition monitoring.

1
Characterize Binding and Target Specificity

Measure association, dissociation, and affinity: ka, kd, and KD.

Compare binding against selected potential cross-reactants to assess target recognition and specificity.

2
Screen Antibody-Pair Compatibility

Use sequential epitope binning to identify candidates that can bind simultaneously under the tested conditions. Remove combinations showing competition or steric interference and prioritize compatible pairs for downstream development.

FOPPR can screen up to four antibodies sequentially on the same antigen-coated sensor in one uninterrupted run, without regeneration between injections.

See the compatibility workflow
3
Qualify and Monitor Antibody Performance

Compare antibody batches and evaluate binding under different buffers, formulations, storage conditions, and sample environments before transfer and during ongoing quality monitoring.

4
Transfer and Optimize Detection

Transfer the selected pair to FONLISA, Simoa, or another assay platform. Optimize the platform-specific format, then establish LoB, LoD, and LoQ and assess recovery, precision, spike recovery across plasma dilutions, parallelism, and matrix interference.

FOPPR can continue to support antibody batch-to-batch comparison and reagent-condition monitoring after assay development.

Distinctive Capability

Up to Four Sequential Antibody Challenges on One Sensor

Conventional workflows often evaluate compatibility two antibodies at a time. FOPPR can challenge the same antigen-coated sensor with up to four antibodies sequentially in one uninterrupted run, preserving the binding history of the surface and reducing the need to restart the experiment after every pair. Each signal change indicates whether the newly introduced antibody can still bind to the progressively occupied surface.

Important distinction

This is sequential cumulative epitope binning, not simultaneous multiplexing. Alternative injection orders may be needed to identify which earlier antibody caused a blocked response and complete the compatibility map.

Conventional Pairwise Evaluation

Conventional methods commonly test ordered antibody pairs through separate assay cycles or a pairwise matrix.

Watch the FOPPR sequential antibody-compatibility workflow on YouTube Watch the four-antibody sequential compatibility workflow on YouTube ↗
One sensor. One antigen-coated surface. Up to four sequential compatibility challenges. No regeneration between injections.

Platform Strategy

FOPPR Complements the Detection Platform You Choose

FOPPR does not require researchers to replace their preferred detection platform. It adds an upstream antibody-qualification step that can be used independently, combined with FONLISA, or integrated into workflows using Simoa or another compatible downstream technology.

01

Use FOPPR Independently

Characterize kinetics, assess selected cross-reactants, screen epitope compatibility, compare antibody batches, and evaluate reagent conditions.

02

Combine FOPPR + FONLISA

Connect antibody qualification with low-background, ultra-sensitive quantification in an integrated selection-to-detection workflow.

03

Transfer to Another Platform

Transfer qualified pairs to Simoa or another compatible assay platform for platform-specific optimization, sensitivity, throughput, or multiplexing.

Accessible Deployment

Compact, Decentralized Antibody Qualification

FOPPR brings real-time antibody characterization closer to the laboratories performing assay development. Its compact format supports qualification work beyond centralized core facilities.

Compact Deployment

Place real-time antibody analysis closer to discovery, translational, and assay-development teams rather than relying exclusively on a centralized characterization facility.

Accessible Real-Time Analysis

Observe association and dissociation behavior directly in a streamlined format designed to support practical antibody-development decisions.

Ongoing Quality Monitoring

Compare antibody batches, reagent formulations, buffers, storage conditions, and sample environments during development and after assay transfer.

Case Study 1

When a Strong Signal May Be the Wrong Signal

FOPPR → Simoa

This study illustrates why antibody specificity should be resolved before an assay is pushed toward lower detection limits.

Clinical need
Lewy body disorders can be difficult to distinguish from Alzheimer’s disease due to overlapping clinical features. Although the target protein is a promising neuroinflammatory biomarker candidate, a previous Ella-based assay had an LLoD of 52.9 pg/mL, leaving multiple samples undetectable, and relied on polyclonal antibodies prone to batch variability and cross-reactivity.
FOPPR finding
Real-time kinetic analysis, sequential epitope binning, and tests against selected related proteins identified candidates with compatible binding behavior. Several alternatives reportedly produced greater responses to a homologous non-target protein than to the target protein under the tested conditions.
Selection and transfer
FOPPR data supported selection of the preferred antibody pair under the tested conditions, based on target binding, epitope compatibility, and low observed cross-reactivity. The pair was transferred to Simoa, where platform-specific optimization reportedly produced an LLoD of 0.618 pg/mL, approximately 86-fold lower than the previous assay.
Takeaway
FOPPR did not directly create the lower Simoa LLoD. It reduced the risk of optimizing an ultra-sensitive assay around antibodies with unsuitable specificity or pair compatibility.

Emer Phillips, University of Amsterdam and Amsterdam UMC. Manuscript in preparation, 2026.

Case Study 2

pTau217: A PTM-Defined Target at Sub-Femtogram Levels

FOPPR → FONLISA

pTau217 presents a different problem. The target is not simply tau at a low concentration; it is tau carrying a specific phosphorylation event at threonine 217. The antibody system must therefore distinguish the intended molecular form while retaining enough sensitivity for plasma measurement.

Step 1 — Affinity Analysis
Step 1: Affinity analysis using FOPPR real-time binding kinetics
Step 2 — Epitope Binning
Step 2: Sequential epitope binning to confirm non-competing antibody pairs
Step 3 — Ultrasensitive Detection
Step 3: Ultrasensitive detection of the selected antibody pair
0.110 fg/mL Reported limit of detection
R² = 0.998 Reported calibration-curve fit
≤10% Triplicate coefficient of variation
86.3-101.2% Reported plasma recovery range

Andrew Ting-Chou Chang1, Venkanagouda Goudar2, Minnie Ting-Hsuan Tsao2, Tony Tsun-Chih Chung2, and Charlotte E. Teunissen3. Poster 2301, AD/PD™ 2026. 1Instant NanoBiosensors B.V., Utrecht, the Netherlands; 2Instant NanoBiosensors Co. Ltd., Taipei City, Taiwan; 3Amsterdam UMC, Amsterdam, the Netherlands.

Broader Applicability

Downstream Platform Example: Portable FONLISA Detection

FONLISA is one possible downstream destination for antibody pairs qualified through FOPPR. External evaluation of a prototype plasma neurofilament light chain assay illustrates the portability and broader biomarker applicability of this downstream platform. Madison Honey, a PhD candidate at Amsterdam University Medical Centre, discusses a study in which FONLISA differentiated control samples from samples from patients with Alzheimer’s disease and showed strong agreement with a single-molecule array assay, supporting further investigation of the platform for rapid biomarker testing.

Researcher perspective on FONLISA plasma NfL detection in Alzheimer’s disease Watch the researcher perspective on FONLISA and plasma NfL ↗

Source: The Video Journal of Dementia
Interview recorded at the AD/PD™ 2024 Congress in Lisbon, Portugal.

Conclusion

Beyond Ultra-Sensitivity

Ultra-sensitive detection cannot compensate for an unsuitable antibody system. FOPPR provides the upstream evidence needed to evaluate binding kinetics, specificity risk, pair compatibility, and batch consistency before downstream optimization begins. Researchers can then use the qualified pair with FONLISA, transfer it to Simoa or another compatible platform, or continue using FOPPR for ongoing reagent monitoring.

From antibody uncertainty to assay decision

Qualify the antibodies before investing in downstream optimization.

Resolve antibody risk upstream, then choose the downstream detection workflow that best fits the required sensitivity, throughput, multiplexing capacity, and application.

Discuss Your Assay

Sources

References

  1. Instant NanoBiosensors. Epitope Binning: A Critical Step in Antibody Development. FOPPR application note.
  2. Instant NanoBiosensors. Neurofilament Light (NfL). Technical note describing affinity analysis, four-antibody testing on one sensor, and pair selection.
  3. The Video Journal of Dementia. Promising FONLISA test for ultrasensitive detection of plasma NfL in Alzheimer’s disease.
  4. Case-study source: Emer Phillips, University of Amsterdam and Amsterdam UMC. Manuscript in preparation, 2026.
  5. pTau217 case-study source: Andrew Ting-Chou Chang1, Venkanagouda Goudar2, Minnie Ting-Hsuan Tsao2, Tony Tsun-Chih Chung2, and Charlotte E. Teunissen3. Poster 2301, AD/PD™ 2026. 1Instant NanoBiosensors B.V., Utrecht, the Netherlands; 2Instant NanoBiosensors Co. Ltd., Taipei City, Taiwan; 3Amsterdam UMC, Amsterdam, the Netherlands.